|Datasheet||Specific References||Reviews||Related Products||Protocols|
|TNFRSF4, RP5-902P8.3, ACT35, CD134, OX40, TXGP1L|
|A DNA sequence encoding the extracellular domain (Met 1-Ala 216) of human TNFRSF4 (NP_003318.1) precursor was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus.|
|In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.|
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
|> 85 % as determined by SDS-PAGE|
|Immobilized Cynomolgus mFc-TNFSF4 (Cat:90088-C04H) at 10 μg/ml (100 μl/well) can bind human TNFRSF4-Fch, The EC50 of human TNFRSF4-Fch is 0.23-0.55 μg/ml.|
|< 1.0 EU per μg of the protein as determined by the LAL method|
|Samples are stable for up to twelve months from date of receipt at -70℃|
|The recombinant human TNFRSF4/Fc is a disulfide-linked homodimer after removal of the signal peptide. The reduced monomer consists of 436 amino acids and has a predicted molecular mass of 48.2 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh TNFRSF4/Fc monomer is approximately 68 kDa due to glycosylation.|
|Lyophilized from sterile PBS, pH 7.4|
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
|Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
OX40 (CD134) and its binding partner, OX40L (CD252), are members of the tumor necrosis factor receptor/tumor necrosis factor superfamily, is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. The interaction between OX40 and OX40L plays an important role in antigen-specific T-cell expansion and survival. OX40 and OX40L also regulate cytokine production from T cells, antigen-presenting cells, natural killer cells, and natural killer T cells, and modulate cytokine receptor signaling. In line with these important modulatory functions, OX40-OX40L interactions have been found to play a central role in the development of multiple inflammatory and autoimmune diseases, making them attractive candidates for intervention in the clinic. Conversely, stimulating OX40 has shown it to be a candidate for therapeutic immunization strategies for cancer and infectious disease.